BSE filing, NSE: VINRKLB. Summary written from the filing by ALFA Finder's alert engine.
Rekvina Laboratories Ltd: key numbers
- Share price
- ₹57.94
- Market cap
- ₹34.93 Cr
- Revenue (annual)
- ₹1.27 Cr
- Net profit (annual)
- ₹-0.25 Cr
- P/E (TTM)
- -102.8×Sector 46.1×
- Promoter holding
- 77.00%+35.70% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rekvina Laboratories Ltd
All →Rekvina Laboratories Business Update
Subsidiary Radiant Parenterals will temporarily shut its manufacturing facility from October 28, 2026. The shutdown supports renovation and installation of an additional vial line.
Rekvina Laboratories Other Announcement
Rekvina Laboratories Limited submitted the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Rekvina Laboratories Management Change
Rekvina Laboratories Limited has appointed Mr. Subrata Samanta as its new Chief Financial Officer and Key Managerial Personnel, effective October 7, 2026.
Rekvina Laboratories Annual General Meeting
Rekvina Laboratories Ltd held its 38th Annual General Meeting on September 29, 2026, approving financial statements and appointing directors.
Rekvina Laboratories Management Change
Rekvina Laboratories Ltd announced a change in its registered office within the city and the resignation of its Managing Director, Mr. Amit Shah.
Rekvina Laboratories Management Change
Mr. Amit Mukesh Shah has resigned as Managing Director and Director of Rekvina Laboratories Limited, effective September 11, 2026.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.